$1.15
-0.03 (-2.54%)
Open$1.18
Previous Close$1.18
Day High$1.18
Day Low$1.14
52W High$45.50
52W Low$0.80
Volume—
Avg Volume788.4K
Market Cap18.75M
P/E Ratio—
EPS$-16.44
SectorBiotechnology
Analyst Ratings
Strong Sell
9 analysts
Price Target
+3,390.4% upside
Current
$1.15
$1.15
Target
$40.14
$40.14
$31.69
$40.14 avg
$63.06
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 548.9K | 523.5K | 509.5K |
| Net Income | 128.1K | 108.5K | 123.6K |
| Profit Margin | 23.3% | 20.7% | 24.3% |
| EBITDA | 177.1K | 173.7K | 174.5K |
| Free Cash Flow | 145.7K | 139.2K | 108.0K |
| Rev Growth | +23.9% | +19.4% | -4.0% |
| Debt/Equity | 0.65 | 0.64 | 0.76 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |